Dry eye disease (DED) is a multifactorial condition in which tear film instability and inflammation play important roles in its etiology. DED can cause symptoms of pain, burning, grittiness, and decreased vision, which, if left untreated, can become increasingly more severe, resulting in damage to the ocular surface. Intense pulsed light (IPL) therapy and radio frequency (RF) treatments have emerged as important modalities for managing DED, particularly in patients with underlying meibomian gland dysfunction (MGD) and rosacea. Both conditions contribute significantly to ocular surface inflammation, tear film instability, and symptoms of DED. Traditional therapeutic methods are often not effective at treating MGD-associated DED as they fail to target the underlying pathophysiology. IPL therapy targets inflammatory pathways by emitting broad-spectrum light that absorbs into the skin, targeting chromophores such as abnormal telangiectatic vessels. The mechanism of action of IPL in DED includes modulation of inflammatory cytokines in the tear film, reduction of meibomian gland inflammation, and improved meibum quality, all promoting enhanced tear film stability. Radio frequency therapy uses electromagnetic current to generate thermal energy to promote skin tightening and rejuvenation. This current generates heat in the skin, thereby stimulating the production of collagen and improving tissue tone. RF treatments work well for MGD as the heat liquefies meibum within the eyelids, thereby enhancing meibomian gland secretion. Clinical studies support the combination of IPL and RF therapies as an effective, adjunctive treatment approach for DED associated with MGD. Treatment typically involves multiple sessions with maintenance treatments required to sustain therapeutic effects, and both therapies are generally well-tolerated. This paper will describe recommended treatment protocols to begin standardizing clinical guidelines for the use of these therapies. The synergistic effect of IPL and RF offers a promising non-pharmacological alternative for patients with DED.